Drug · DIN 02146967
DIGIBIND
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since February 6, 2013; first marketed December 31, 1995.
- Drug Identification Number (DIN)
- 02146967
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Digitalis antitoxin V03AB24
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DIGOXIN IMMUNE FAB (OVINE) | 38 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 15, 2001: NOC 2158New Drug Submission (NDS) · Change in manufacturer name
- September 12, 1996: NOC 4343New Drug Submission (NDS)
- November 22, 1995: NOC 4984Supplement to a New Drug Submission (SNDS) · Change in manufacturing